Faculty of Pharmacy, Pham Ngoc Thach University of Medicine, Ho Chi Minh, Vietnam
ThEMAS (Techniques for Evaluation and Modeling of Health Actions) TIMC-IMAG (Techniques for Biomedical Engineering and Complexity Management - Informatics, Mathematics and Applications) UMR CNRS (National Institute of Sciences of the Universe - Research Unit 5525), Grenoble Alpes University, Grenoble, France.
Eur J Hosp Pharm. 2021 Jul;28(4):193-200. doi: 10.1136/ejhpharm-2020-002642. Epub 2021 Apr 21.
Clinical pharmacists' interventions (PIs) are an important element in ensuring good pharmaceutical care. We aimed to develop and validate a comprehensive multidimensional tool for assessing the potential impact of PIs for daily practice of medication review.
Experts of the French Society of Clinical Pharmacy (SFPC) developed the CLinical, Economic and Organisational (CLEO) tool, consisting of three independent dimensions concerning clinical, economic and organisational impact. They were asked to analyse 30 scenarios of PIs, and re-rated 10 PIs with a washout of 1 month (internal validation). Then, seven external experts not involved in the development of the tool rated 60 scenarios collected when using the CLEO in daily practice. Inter- and intra-rater reliabilities were determined by calculation of the intra-class correlation (ICC). Users' satisfaction and acceptability of the tool were assessed on a 7-level Likert scale with a 17-item questionnaire.
For internal reliability, the inter-rater reliability for the CLEO tool was good for clinical dimensions (ICC=0.693), excellent for economic dimensions (ICC=0.815) and fair for organisational dimensions (ICC=0.421); and the intra-rater reliability was good for clinical dimensions (ICC=0.822), excellent for economic dimensions (ICC=0.918) and good for organisational dimensions (ICC=0.738). For external reliability, the inter-rater reliability was good for clinical dimensions (ICC=0.649), excellent for economic dimensions (ICC=0.814) and fair for organisational dimensions (ICC=0.500). CLEO was viewed as relevant (mean±SD 4.93±1.27), acceptable (4.81±1.78), practicable (5.56±1.45) and precise (5.38±1.47).
CLEO is a comprehensive tool assessing clinical, economic and organisational impacts of PIs which has been developed, validated and was reliable and feasible for use in routine clinical practice.
临床药师干预(PI)是确保良好药学服务的一个重要因素。我们旨在开发和验证一种综合多维工具,以评估 PI 对药物审查日常实践的潜在影响。
法国临床药学学会(SFPC)的专家开发了 CLinical、Economic 和 Organisational(CLEO)工具,该工具由三个独立的维度组成,分别涉及临床、经济和组织影响。要求他们分析 30 个 PI 场景,并在 1 个月的洗脱期后重新评估 10 个 PI(内部验证)。然后,7 位未参与工具开发的外部专家对在日常实践中使用 CLEO 时收集的 60 个场景进行了评估。通过计算组内相关系数(ICC)来确定内部和外部评估者的可靠性。使用 7 级李克特量表和 17 项问卷评估工具的用户满意度和可接受性。
对于内部可靠性,CLEO 工具的组间可靠性对于临床维度来说很好(ICC=0.693),对于经济维度来说极好(ICC=0.815),对于组织维度来说尚可(ICC=0.421);组内可靠性对于临床维度来说很好(ICC=0.822),对于经济维度来说极好(ICC=0.918),对于组织维度来说尚可(ICC=0.738)。对于外部可靠性,组间可靠性对于临床维度来说尚可(ICC=0.649),对于经济维度来说极好(ICC=0.814),对于组织维度来说尚可(ICC=0.500)。CLEO 被认为是相关的(平均值±标准差 4.93±1.27)、可接受的(4.81±1.78)、可行的(5.56±1.45)和准确的(5.38±1.47)。
CLEO 是一种综合工具,可评估 PI 的临床、经济和组织影响,该工具已开发、验证并在常规临床实践中可靠且可行。